Oncotarget

Research Papers:

PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth

Narinder Sharma, Rajesh Nanta, Jay Sharma, Sumedha Gunewardena, Karan P. Singh, Sharmila Shankar and Rakesh K. Srivastava _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:32039-32060. https://doi.org/10.18632/oncotarget.5055

Metrics: PDF 1957 views  |   HTML 1934 views  |   ?  


Abstract

Narinder Sharma1, Rajesh Nanta1, Jay Sharma2, Sumedha Gunewardena3, Karan P. Singh4, Sharmila Shankar5,6, Rakesh K. Srivastava1,5

1Department of Pharmacology, Toxicology and Therapeutics, and Medicine, University of Kansas Medical Center, Kansas City, KS, 66160, USA

2Celprogen Inc. Torrance, CA 90503, USA

3Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, 66160, USA

4Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35205, USA

5Kansas City VA Medical Center, Kansas City, MO, 66128, USA

6Department of Pathology, University of Missouri-School of Medicine, Kansas City, MO, 64108, USA

Correspondence to:

Rakesh K. Srivastava, e-mail: rakesh.srivastava@va.gov; rsrivastava.lab@gmail.com

Keywords: pancreatic cancer, PI3K/AKT/mTOR, sonic hedgehog, cancer stem cell, Gli

Received: July 06, 2015     Accepted: September 22, 2015     Published: October 05, 2015

ABSTRACT

Cancer stem cells (CSCs) play major roles in cancer initiation, progression, and metastasis. It is evident from growing reports that PI3K/Akt/mTOR and Sonic Hedgehog (Shh) signaling pathways are aberrantly reactivated in pancreatic CSCs. Here, we examined the efficacy of combining NVP-LDE-225 (PI3K/mTOR inhibitor) and NVP-BEZ-235 (Smoothened inhibitor) on pancreatic CSCs characteristics, microRNA regulatory network, and tumor growth. NVP-LDE-225 co-operated with NVP-BEZ-235 in inhibiting pancreatic CSC's characteristics and tumor growth in mice by acting at the level of Gli. Combination of NVP-LDE-225 and NVP-BEZ-235 inhibited self-renewal capacity of CSCs by suppressing the expression of pluripotency maintaining factors Nanog, Oct-4, Sox-2 and c-Myc, and transcription of Gli. NVP-LDE-225 co-operated with NVP-BEZ-235 to inhibit Lin28/Let7a/Kras axis in pancreatic CSCs. Furthermore, a superior interaction of these drugs was observed on spheroid formation by pancreatic CSCs isolated from Pankras/p53 mice. The combination of these drugs also showed superior effects on the expression of proteins involved in cell proliferation, survival and apoptosis. In addition, NVP-LDE-225 co-operated with NVP-BEZ-235 in inhibiting EMT through modulation of cadherin, vimentin and transcription factors Snail, Slug and Zeb1. In conclusion, these data suggest that the combined inhibition of PI3K/Akt/mTOR and Shh pathways may be beneficial for the treatment of pancreatic cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5055